Lantheus Holdings, Inc. (LNTH): Total Liabilities
$1.14B
As of 2025-12-31
$1.10B
As of 2026-06-30
+9.2%
3-year compound annual growth
+26.2%
5-year compound annual growth
+10.3%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.14B | +27.5% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $892.33M | +6.8% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $835.26M | -4.4% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $874.11M | +118.9% | 2024-02-22, Balance as of period end |
| 2021-12-31 | $399.35M | +12.3% | 2023-02-23, Balance as of period end |
| 2020-12-31 | $355.62M | +22.1% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $291.32M | -21.0% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $368.83M | +2.3% | 2020-02-25, Balance as of period end |
| 2017-12-31 | $360.57M | -0.5% | 2019-02-20, Balance as of period end |
| 2016-12-31 | $362.41M | -15.3% | 2018-02-26, Balance as of period end |
| 2015-12-31 | $427.67M | -11.3% | 2017-02-23, Balance as of period end |
| 2014-12-31 | $482.42M | n/a | 2016-03-02, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | 2025-12-31 | $1.14B | +27.5% |
| QuidelOrtho Corp (QDEL) | 2025-12-28 | $3.85B | +11.9% |
| Neogen Corp (NEOG) | 2026-05-31 | $1.25B | -8.7% |
| Myriad Genetics Inc (MYGN) | 2025-12-31 | $338.60M | +3.7% |
| Idexx Laboratories Inc (IDXX) | 2025-12-31 | $1.75B | +2.8% |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | $170.73M | -46.5% |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | $34.81M | -4.3% |
| Immucell Corp (ICCC) | 2025-12-31 | $15.48M | -12.0% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | $12.39M | +53.8% |
Compare LNTH, QDEL, NEOG, MYGN side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗